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ABSTRACT
XLF-Cernunnos (XLF) is a component of the DNA
ligase IV–XRCC4 (LX) complex, which functions
during DNA non-homologous end joining (NHEJ).
Here, we use biochemical and cellular approaches
to probe the impact of XLF on LX activities. We
show that XLF stimulates adenylation of LX com-
plexes de-adenylated by pyrophosphate or follow-
ing LX decharging during ligation. XLF enhances
LX ligation activity in an ATP-independent and
dependent manner. ATP-independent stimulation
can be attributed to enhanced end-bridging. Whilst
ATP alone fails to stimulate LX ligation activity, addi-
tion of XLF and ATP promotes ligation in a manner
consistent with XLF-stimulated readenylation linked
to ligation. We show that XLF is a weakly bound
partner of the tightly associated LX complex and,
unlike XRCC4, is dispensable for LX stability. 2BN
cells, which have little, if any, residual XLF activity,
show a 3-fold decreased ability to repair DNA
double strand breaks covering a range of complex-
ity. These findings strongly suggest that XLF is not
essential for NHEJ but promotes LX adenylation and
hence ligation. We propose a model in which XLF, by
in situ recharging DNA ligase IV after the first liga-
tion event, promotes double stranded ligation by a
single LX complex.
INTRODUCTION
DNA non-homologous end-joining (NHEJ) is the major
mechanism for the repair of radiation induced DNA
double strand breaks (DSBs) in mammalian cells. Cell
lines lacking NHEJ components are exquisitely radiosen-
sitive and DSB repair defective (1,2). NHEJ also functions
to eﬀect rearrangements at site-speciﬁc DSBs introduced
during V(D)J recombination (3). Consequently, viable
mice lacking NHEJ proteins show severe combined immu-
nodeﬁciency (SCID). Patients deﬁcient in NHEJ com-
ponents have also been described. Most patients show
varying degrees of combined immunodeﬁciency, microce-
phaly and developmental delay and cell lines derived from
them display radiosensitivity, which leads to the classi-
ﬁcation of radiosensitive-(RS)-SCID (4–7). One patient
received radiotherapy and dramatically over-responded
to treatment demonstrating clinical radiosensitivity (8,9).
The ﬁrst step of NHEJ is binding of the heterodimeric
Ku protein to double stranded (ds) DNA ends. Crystal-
lography studies on Ku have shown that it can encircle
DNA with a central core of suﬃcient diameter to allow the
threading and translocation of Ku onto dsDNA (10).
Once bound to DNA, Ku recruits the DNA–PK catalytic
subunit (DNA–PKcs), creating the active DNA–PK
holoenzyme (1,2). Increasing evidence suggests that
DNA–PK undergoes autophosphorylation, which regu-
lates the process and/or facilitates the recruitment of addi-
tional proteins required for end processing, such as
Artemis (11,12). The assembled DNA–PK complex facil-
itates the recruitment of a ligation complex encompassing
XRCC4 and DNA ligase IV (13,14).
XLF-Cernunnos, hereafter called XLF, was identiﬁed
via the analysis of a class of RS-SCID patients with fea-
tures closely resembling those of LIG4 syndrome patients,
a disorder caused by mutations in DNA ligase IV (6,7,15).
This strongly suggested that XLF is a component of the
NHEJ machinery, which is substantiated by the ﬁnding
that XLF interacts with XRCC4 and is co-recruited with
NHEJ components to DSBs (15,16). Furthermore, it has
recently been reported that Ku plays a role in recruiting
XLF to DSBs (17). Interestingly, XLF was predicted, and
has now been shown, to have a structure similar to, but
distinct from, that of XRCC4 with an N-terminal globular
head domain and C-terminal coiled coil structure, which is
shorter than that in XRCC4 and directed towards the
N-terminal region (15,18,19). Furthermore, XLF repre-
sents the mammalian homologue of the yeast Nej1p pro-
tein, a factor regulating NHEJ in yeast (20). Since both
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binding activity and display normal DNA–PK activity,
the available data provides strong evidence that XLF is
a further factor required for ligation during NHEJ (6,15).
The co-immunoprecipitation of XLF with LX has lead to
the suggestion of a tripartite XLF–XRCC4–ligase IV
complex, although a more recent study has suggested
that XLF does not impact on LX association or DSB
recruitment (16). XLF has been reported to promote LX
ligation potentially by enhancing end-bridging because of
its ability to bind DNA (15,21,22). However, multiple
proteins are able to promote end-bridging in vitro includ-
ing DNA–PKcs and Ku, and DNA ends might also be
partially tethered by higher order DNA structure
(23–25). XLF has also been reported to be involved specif-
ically in the ligation of mismatched and noncohesive DNA
ends (21,26). Here, we examine in further detail the impact
of XLF on LX activities.
The ligation reaction involves an initial charging step
generating a DNA ligase IV–adenylate complex followed
by transfer of the AMP moiety to the 50 phosphate on
DNA creating a DNA–adenylate complex and releasing
uncharged DNA ligase IV, which needs to be re-adeny-
lated for subsequent ligation. A recent study characteriz-
ing LX based on its nick ligation activity highlighted that,
in contrast to other DNA ligases, LX re-adenylation fol-
lowing ligation proceeds very slowly and is rate limiting
in vitro (27). In support of this, we have never observed
any stimulation of LX-mediated ds ligation by ATP (28).
Here, we have used biochemical and cellular approaches
to probe the role of XLF in NHEJ. We provide the ﬁrst
demonstration that XLF stimulates LX adenylation fol-
lowing ligation, which enhances the ability of LX com-
plexes to stimulate ds ligation in the presence of ATP.
To gain insight into the in vivo impact of XLF function,
we examined two lines harbouring mutations in XLF. We
demonstrate that 2BN cells have little, if any, residual
XLF function but manifest only a 3-fold decrease in
rejoining DSBs covering a range of complexities. Our ﬁnd-




Primary ﬁbroblasts, 1BR3 (control), 2BN and F07/402
(XLF-deﬁcient), 180BR and 495GOS (LIGIV-deﬁcient),
hTERT immortalized ﬁbroblasts, 48BRhT (control),
2BNhT, 180BRhT, 495GOShT, and SV-40 transformed
human ﬁbroblasts, MRC5BIVA, were grown in minimal
essential medium (MEM) as described previously (6,29).
Human PreB Nalm6 (wild type) and N114P2 (Lig4 null)
were grown in RPMI medium supplemented with 10%
foetal calf serum (FCS), penicillin and streptomycin.
Chinese hamster ovary (CHO) cells, AA8 (wild type)
and XR-1 (XRCC4 null) and mouse embryonic ﬁbroblasts
(MEFs) MEF22 and LigIV
 / p53
 /  were grown in
MEM, supplemented with 10% FCS, penicillin and
streptomycin.
XLF was cloned into pCI neo-n-FLAG and c-HA, orig-
inally from Promega (Madison, USA) and modiﬁed by Dr
E. Taylor. To introduce the 11insT mutation into XLF
cDNA, QuickChange
R XL Site-Directed Mutagenesis kit
from Stratagene was used (Cambridge, UK). MRC5BIVA
were transfected using Fugene (Roche, Burgess Hill, UK).
Neocarzinostatin and Etoposide Sigma-Aldrich,
(Dorset, UK) were added at the indicated concentrations
and Etoposide was removed after 1h. AMPCPP was from
Jena Bioscience GmbH (Jena, Germany).
Immunofluorescence, immunoblotting and antibodies
Immunoﬂuorescence analysis was carried out as pre-
viously described (30). Whole cell extracts for immuno-
blotting and immunoprecipitations were prepared as
described previously (15). a-DNA ligase IV and
a-XRCC4 rabbit antibodies were from Serotec (Oxford,
UK). a-XLF rabbit antibody was generated against bac-
terially expressed XLF by Eurogentec (Seraing, Belgium).
a-Ku70 goat antibody and a-cMYC (9E10) were from
Santa Cruz Biotechnology (Santa Cruz, CA). ANTI-
FLAG M2 monoclonal antibody was purchased from
Sigma-Aldrich (Poole, UK). 6xHIS monoclonal anti-
body came from Clontech (Palo Alto, CA). Anti-HA anti-
body (12CA5) was from Cancer Research UK. a–g-H2AX
mouse antibody was from Upstate Technology
(Buckingham, UK). Anti-rabbit, anti-mouse and anti-
goat secondary antibodies were purchased from Dako
(Glostrup, Denmark).
For in vitro transcription–translation system (TNT),
pcDNA3-n-His-LIG4 (9), pCI neo-n-Myc-XRCC4 and
pCI neo-n-FLAG-XLF (this work) were expressed using
Promega TNT T7 Quick couple transcription/translation
system (Madison, USA).
Purification of DNA ligase IV–XRCC4 complexes,
DNA–PKand XLF
Theexpressionandpuriﬁcation ofDNAligaseIV–XRCC4
complexes and XLF was performed as described previ-
ously (22,31). For XLF puriﬁcation, the bacterial pellet
was lysed in 50mM Tris pH 8.0, 5mM EDTA, 400mM
NaCl, 1mM DTT, 1mM PMSF and 1% Triton X-100,
followed by sonication and clariﬁcation by centrifugation.
GST-XLF was bound to GST beads and washed with
lysis buﬀer. When required, the GST tag was removed by
thrombin treatment. The protein was concentrated using
Vivascience 0.5ml column (Sartorius). DNA–PK was
puriﬁed as described previously (32).
Adenylation and ligation
Adenylation and ligation were performed as described
previously (28,31). Brieﬂy, for adenylation reactions, LX
complexes were incubated in the presence of 5mM diso-
dium pyrophosphate for 15min at room temperature in
20mM Tris–HCl, pH 8.0, 50mM NaCl. Pyrophosphate
was removed using a Vivascience 0.5ml column
(Sartorius). The complexes were incubated in the presence
of puriﬁed XLF or 0.1mg/ml of BSA and a-
32P-ATP
(2mCi, 66nM ﬁnal concentration) (GE Healthcare,
Buckinghamshire, UK). For ligations, a 445-bp DNA
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(Stratagene) by digestion with PstI and AﬂIII (New
England Biolabs). For the reactions, the indicated
amount of protein complexes were incubated for the indi-
cated times in 20ml of ligation reaction (50mM triethano-
lamine, pH 7.5, 2mM Mg(OAc)2, 2mM dithiothreitol,
0.1mg/ml bovine serum albumin, 9% polyethylene
glycol) with the labelled substrate and in the presence or
absence of 2mM ATP or AMPCPP.
Bridgingassayfor theassociation oftwo DNA molecules
This assay was performed as described previously (24,25).
The DNA fragment was the 445-bp pBluescript cohesive
fragment used for ligation analysis. This substrate was
labelled with a biotin group using the BrightStar
Psoralen-Biotin Nonisotonic labelling Kit (Ambion,
Warrington, UK). The binding buﬀer was the one used
for ligation (50mM triethanolamine, pH 7.5, 2mM
Mg(OAc)2, 2mM dithiothreitol, 0.1mg/ml bovine serum
albumin) without polyethylene glycol and supplemented
with 40mM KCl and 1mM ATP. The reaction was car-
ried out at room temperature for 15min.
siRNA transfection
Cells were untreated or transfected twice with scramble or
XLF siRNA (0.2mM) from Dharmacon SMART pool
(Dharmacon, USA) using HiPerFect transfection reagent
(QIAGEN, Hilden, Germany).
RESULTS
XLFstimulates ligase IV re-adenylation following ligation
The ﬁrst step of the ligation reaction is binding of AMP to
the active site lysine of DNA ligase IV generating an ade-
nylated ligase with the release of pyrophosphate. Firstly,
we examined whether XLF impacts upon LX adenylation
activity. Since we were unable to purify a co-expressed
trimeric complex because of the weak association of
XLF with LX at greater than physiological salt concentra-
tions (see below), we used separately puriﬁed, bacterially
expressed XLF and insect cell-expressed LX. LX is
expressed in insect cells as a pre-adenylate complex and
assessment of adenylation activity is normally carried out
following de-adenylation by inorganic pyrophosphate
(PPi), which causes AMP release. Incubation of the
de-adenylated complex with radioactively labelled
a-ATP generates a labelled AMP–LX (adenylate) complex
that can be detected on an SDS–PAGE gel. Using 5 pmol
of XLF and 1 pmol of LX, we observed 2–3-fold stimula-
tion in the rate of adenylation over 20min (Figure 1A; gels
shown in Supplementary Figure S1A). A similar degree of
stimulation was observed using between 5 and 30 pmol
XLF (data not shown).
We and others have previously observed that re-adeny-
lation of LX following ligation is very ineﬃcient (27,28).
Therefore, we considered the possibility that XLF might
play a role in recharging LX following ligation. We ﬁrst
examined the impact of ligatable DNA on adenylation
using LX complexes previously de-adenylated by PPi
treatment. We utilized a 445-bp pBluescript fragment,
which we have previously used in ds ligations (28), and
observed that the presence of DNA decreases adenylate
complex formation regardless of the presence of XLF
(Figure 1B and Supplementary Figure S1B). This suppres-
sive impact was more marked at later times consistent with
ligation causing LX de-adenylation thereby reducing the
overall amount of adenylate complex observed.
To determine whether XLF stimulates re-adenylation
following ligation, we adapted our assay to examine ade-
nylate complex formation without prior de-charging of
LX complexes by PPi treatment. Instead, we examined
re-adenylation of LX following de-charging by ligation.
To achieve this, we allowed ligation to take place in
the absence of ATP, with or without XLF, during
a 15min pre-incubation step prior to addition of radio-
labelled a-ATP to monitor adenylate complex formation
(Figure 1C and Supplementary Figure S1C). XLF pro-
moted LX adenylation following incubation in the pre-
sence of DNA, while such activity occurred slowly in
the absence of XLF, providing the ﬁrst demonstration
that signiﬁcant re-adenylation of LX can occur following
ligation. To verify that ligation had taken place, we mon-
itored ligation during the pre-incubation phase in the
absence of ATP and subsequently when ATP (with or
without XLF) was added (Figure 1D). We observed
ligation products during the pre-incubation reaction con-
sistent with de-adenylation occurring as a consequence of
ligation. However, ligation peaked at 15min and further
stimulation following addition of ATP was not observed
either in the presence or absence of XLF. This is likely due
to the fact that only a small fraction of LX complexes are
recharged during the reaction since optimization of our
ability to detect LX–
32P–adenylate complex formation
required using radiolabelled ATP without added cold
ATP. Thus, the ATP concentrations (66 nM) are likely
below the optimal Km for ATP for DNA ligase IV. The
presence of XLF during the 15min pre-incubation step did
not increase either the rate of LX adenylation (Figure 1C)
or the level of ligation (data not shown), suggesting
that XLF may not enhance ligation without prior
de-adenylation of LX. However, in this experiment an
excess of LX to substrate (5:1) was utilized, potentially
limiting any ability to detect XLF stimulatory activity.
We, therefore, modiﬁed the assay to examine the impact
of XLF on ligation under LX rate-limiting conditions
(1:4 ratio of LX to DNA ends) but still failed to observe
any marked stimulation (Figure 1E). These ﬁndings show
that while XLF does not markedly stimulate ligation
during the pre-incubation phase, it markedly enhances
the rate of adenylation. Thus, we demonstrate that there
is an impact on LX re-charging that cannot be attributed
to any marked impact of XLF on ligation. We also
examined the stimulation of adenylation in the presence
of non-ligatable DNA. We used a blunt ended DNA sub-
strate since blunt ended DNA is a poor substrate in
our in vitro ligation reaction. Blunt-ended DNA failed
to stimulate either adenylation or ligation activity
(Supplementary Figure S2). Thus, we conclude that the
stimulation of adenylation by XLF in this assay follows
de-adenylation by ligation.
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lation using physiologically relevant ratios of XLF and
LX, we used a-XRCC4 antibodies to immunoprecipitate
LX-XLF complexes from extracts from a human pre-B
cell line using 0.12M NaCl and employed a high salt
(1M NaCl) wash to discharge XLF (see below). This
allows a comparison of the impact of XLF in the same
cellular background. De-adenylation of LX was carried
out by PPi treatment or by incubation with DNA
(445-bp pBluescript fragment). XLF stimulated LX
adenylation activity following PPi treatment (+PPi, 1M
NaCl versus +PPi, 0.12M NaCl) but strikingly, stimula-
tion was even greater when LX was de-charged by DNA
(+DNA, 1M NaCl versus +DNA, 0.12M NaCl)
(Figure 1F). Thus, even though our biochemical studies
require a ratio of XLF to LX greater than one, potentially
due to a percentage of inactive XLF in the XLF prepara-
tions, the ratio of XLF to LX obtained by co-immunopre-
cipitation was also able to stimulate LX re-adenylation
linked to ligation, conﬁrming our in vitro ﬁndings.
ATP-dependent and independent stimulation ofLX
double-stranded ligation by XLF
Previous studies have shown that XLF stimulates LX ds
ligation activity (21,22). Our ﬁnding that XLF stimulates
LX recharging following ligation predicted that XLF stim-
ulation of ligation should be ATP-dependent. Although
we were unable to observe XLF stimulation of ligation
in the experiments described above (Figure 1D), this was
potentially attributable to the low ATP concentration uti-
lized in the assay. We, therefore, examined the impact of
concentrations of ATP in the physiological range (2mM)
on the ability of XLF to stimulate LX ds ligation. First,
we titrated the amount of XLF stimulating 125fmol LX,
which eﬀects only a low level of ligation and observed a
broad peak of stimulation from 2.5 to 30pmol XLF,
which varied slightly with individual LX preparations
(Figure 2A). We next examined the ability of 17pmol
XLF to stimulate ligation eﬀected by diﬀering amounts
of LX in the presence or absence of ATP (Figure 2B). In
the absence of XLF, little ds ligation was observed. In
agreement with previous ﬁndings and the discussion
above, addition of ATP alone did not stimulate LX activ-
ity consistent with the dramatically reduced ability of LX
to undergo re-adenylation post ligation (Figure 2B, com-
pare left and right panels) (27,28). XLF provided some
stimulation in the absence of ATP but further stimulation
was observed in the presence of ATP (Figure 2B, right
panel). Signiﬁcantly, when high amounts of LX were
employed (50 fmol) with or without ATP, XLF provided
no further stimulation, consistent with the notion that LX
Figure 1. XLF stimulates ligase IV re-adenylation following ligation. (A) LX was treated with pyrophosphate (PPi) for 15min at room temperature.
Following dialysis, 1pmol LX was incubated with a-
32P-ATP with or without 5pmol XLF. XLF stimulated LX adenylation activity 2.5-fold. Results
and error bars are the mean and SD of two experiments. (B) Following PPi treatment and dialysis, 1pmol LX was incubated with a-
32P-ATP, with
or without 30pmol XLF and 0.2pmol DNA ends. (C) One picomole LX was incubated with 0.2pmol DNA ends for 15min to allow ligation and
hence de-adenylation. a-
32P-ATP was then added with or without 5pmol XLF. XLF enhanced adenylation 3-fold. Whether XLF was present or
absent during the pre-incubation step did not change the level of adenylation. Results are the mean and SD of two experiments. (D) Samples treated
as in (C) were examined for ligation by gel electrophoresis. Ligation occurred during the preincubation step and peaked by 15min. (E) Total 0.2pmol
LX were incubated with 0.8pmol DNA ends with or without 1pmol XLF without ATP for 15min. Samples were examined for ligation. XLF did not
impact upon the level of ligation. (F) Two milligrams WCE from human pre-B control cells (Nalm6) were immunoprecipitated with a-XRCC4
antibodies, split in half and washed either in buﬀer containing 1 or 0.12M NaCl. Samples were treated with or without PPi in the presence or
absence of  35pmol DNA ends and were examined for adenylation activity. LX-aAMP is the adenylated LX complex. Immunoprecipitated samples
were subjected to immunoblot analysis using a-DNA ligase IV antibodies. The graph shows arbitrary units of intensity of adenylation normalized to
protein levels.
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independent ligation events. These ﬁndings provide strong
evidence that XLF can stimulate adenylation under phy-
siological ATP concentrations and moreover, that such
stimulation can enhance ds ligation.
It has been suggested that XLF might function as a
bridging factor to facilitate alignment and rejoining of
ds DNA ends (22,33). To examine this, we used a pull-
down assay in which the 445-bp duplex substrate used for
ligation was biotin labelled and bound to magnetic
streptavidin beads and incubated together with XLF and
32P-end-labelled substrate. Intermolecular substrate asso-
ciation was assessed by monitoring the ability of strep-
tavidin beads to retain the
32P-labelled duplex following
multiple washes (Figure 2C). XLF enhanced the recovery
of radiolabelled DNA associated with beads demons-
trating that it facilitates DNA end-bridging. As a control,
DNA–PK holoenzyme (DNA–PKcs–Ku80/70), which
also promotes end-bridging, caused a similar increase in
duplex-bridging activity, and XLF and DNA–PK holoen-
zyme together did not show any additive eﬀect (32). These
ﬁndings support the notion that XLF promotion of liga-
tion in the absence of ATP might be attributable to its
ability to promote end-bridging. The experiments carried
out in Figure 1D used a low XLF to LX molar ratio
( 5:1), optimized to observe the stimulatory eﬀect of
XLF on LX adenylation. In contrast, the ligation experi-
ments in Figure 2B used a higher molar ratio of XLF to
LX ( 75:1). Since the ratio of LX to DNA ends remains
essentially the same ( 5:1 versus  2:1, respectively), it is
possible that the higher level of XLF is required to pro-
mote DNA end bridging. Multiple proteins promote end-
bridging and stimulate in vitro ligation reactions. Since
XLF interacts with LX, we considered that this might
provide an added impact on ligation in vivo but was unli-
kely to represent the unique function of XLF in NHEJ.
The ATP-dependent impact of XLF is unique, however,
and consistent with the notion that XLF promotes LX
recharging. To further examine this, we looked at the
impact of XLF on the kinetics and maximal level of liga-
tion with or without ATP (Figure 2D). In the absence of
XLF (diamonds), there is hardly any ligation going on. In
the absence of ATP, stimulation of ligation by XLF
occurred within the ﬁrst few minutes and little further
stimulation was observed (squares). ATP together with
XLF also enhanced the ligation within the ﬁrst few min-
utes (triangles) but the maximal level obtained was higher
than that observed in the absence of ATP. We conclude
that XLF stimulates ds LX ligation activity in two ways,
one being ATP-independent and the other ATP-depen-
dent. In the presence of ATP, XLF enhances the maximal
level of ligation consistent with our ﬁndings that it pro-
motes recharging of LX following ligation. We also used
an ATP analogue, AMPCPP, which cannot be hydrolysed
to AMP and thus cannot generate an LX–adenylate com-
plex. The level of stimulation of ligation observed in the
Figure 2. XLF stimulates LX double stranded ligation in an ATP-dependent and independent manner. (A) On the left panel, substrate ligated by
T4 and unligated substrate were run as controls. On the right panel, 125fmol LX was incubated with 50-
32P-end-labelled DNA fragment (445bp) and
increasing amounts of XLF. Ligation products were analysed by gel electrophoresis. XLF stimulated ligation. (B) Increasing amounts
of LX complexes were incubated with or without 17pmol GST–XLF in the absence (left panel) or presence (right panel) of 2mM ATP and
50-
32P-end-labelled substrate. (M, monomer) No multimers formed in the absence of XLF. XLF stimulated LX ligation in the absence of ATP
but further stimulation was observed in the presence of ATP. (C) Twenty-ﬁve femtomoles 50-
32P-end-labelled DNA fragment were incubated with
100fmol biotinylated substrate at RT for 15min and the presence of co-associated radioactive substrate estimated. GST–XLF (17pmol) shows the
same level of bridging as 9.7pmol of DNA–PK holoenzyme or 1.3pmol of Ku. (D) Five femtomoles LX complexes were incubated with 15pmol
XLF and 50-
32P-end-labelled DNA fragment. Ligation was estimated at time points indicated. No ligation occurred in the absence of XLF. XLF
stimulated ligation in the absence of ATP but the maximum level of ligation was increased in the presence of XLF and ATP. (E) Five femtomoles
LX complexes were incubated with 10pmol XLF and 50-
32P-end- labelled DNA fragment. XLF could not stimulate the ligation reaction in the
presence of AMPCPP to the level reach in the presence of ATP.
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presence of ATP (Figure 2E) and, interestingly, was simi-
lar to that observed in the absence of ATP (Figure 2D).
XLF isdispensable for DNA ligase IV stability and
is aweakerbinding partner ofthe stableLX complex
To examine XLF function in vivo, we used the 2BN cell
line, which was derived from a patient with SCID with a
single base pair (+T) insertion at position 11 (11insT) in
the ﬁrst coding exon of XLF (6,15). The insertion intro-
duces a frameshift and creates a termination codon at
position 139. Thus, the mutant protein only shares the
ﬁrst four amino acids with the wild-type protein. Using
polyclonal antibodies raised to bacterially expressed, full-
length, human XLF (a-XLF), we were unable to detect
any residual XLF protein in 2BN cell extracts by immu-
noﬂuorescence or immunoblotting (Figure 3A and B)
despite a strong signal obtained with control cell extracts
consolidating previous analysis of 2BN cells using a dis-
tinct a-XLF antibody (15). We were also unable to detect
any smaller XLF fragments in 2BN cell extracts providing
no evidence for translational re-initiation (data not
shown). Given the lack of any signiﬁcant XLF expression
in 2BN cells, we examined the interdependence of XLF,
XRCC4 and DNA ligase IV expression on protein
stability. Immunoblotting and immunoﬂuorescence
showed that XRCC4 and DNA ligase IV are expressed
normally and localize to the nucleus in 2BN cells
(Figure 3A and B). In contrast, XR-1 cells, which lack
XRCC4, express low levels of DNA ligase IV, as reported
previously (Figure 3B) (34). Moreover, XRCC4 expres-
sion in a LIG4 null cell line, N114P2, is approximately
one third reduced compared to the parent line, Nalm6
(Figure 3B). XLF was expressed normally in DNA
ligase IV-defective N114P2 cells. XLF expression in
XR-1 cells could not be assessed since the a-XLF antibo-
dies do not cross-react with hamster XLF. Collectively,
these ﬁndings demonstrate that, whereas XRCC4 and
DNA ligase IV are co-dependent for normal expression,
XLF is dispensable for the stability of both XRCC4 and
DNA ligase IV. Conversely, DNA ligase IV is dispensable
for XLF stability and nuclear localization.
As the tightly associated LX complex is stable under
high ionic strength, we examined the stability of the
XLF–LX complex. We examined the impact of ionic
strength on the interaction between DNA ligase IV,
XRCC4 and XLF using cell extracts derived from
MRC5BIVA cells expressing N-terminal FLAG-tagged
XLF (F-XLF). a-FLAG antibodies eﬃciently co-immu-
noprecipitated DNA ligase IV under physiological salt
conditions (0.12M NaCl) but the interaction was substan-
tially reduced at 0.5M NaCl and essentially abolished at
1M NaCl (Figure 3C). This contrasts with the strong
interaction between XRCC4 and DNA ligase IV which
is stable even at 1M NaCl (35). We also examined
interaction following expression of S
35-methionine radi-
olabelled, tagged proteins (HIS-LigIV, MYC-XRCC4
and FLAG-XLF) in a transcription-translation system
(Figure 3D). a-MYC antibodies eﬃciently co-immunopre-
cipitated XLF at 0.12mM NaCl but not at 1M NaCl.
Figure 3. XLF is dispensable for DNA ligase IV stability and can be
dissociated from the stable LX complex. (A) 1BR3 and 2BN cell lines
were analysed by immunoﬂuorescence using antibodies against DNA
ligase IV, XRCC4 and XLF. 2BN cells lack XLF but express normal
levels of ligase IV and XRCC4. (B) Left panel: 100mg of whole cell
extract (WCE) from control (48BRhT) and XLF-deﬁcient (2BNhT)
were analysed by immunoblotting with a-DNA ligase IV, a-XRCC4
and a-XLF antibodies. Immunoblots were re-probed with a-Ku70 anti-
body as a loading control. (A) and (B) show that 2BN cells express
normal levels of DNA ligase IV and XRCC4 but not XLF. Middle
panel: 15mg of human control (Nalm6) and DNA ligase IV null pre-B
cells (N114P2) were examined by immunoblotting. XRCC4 protein
levels were reduced in the N114P2 cells compared to control cells but
the levels of XLF were normal. Right panel:6 0 mg of WCE from CHO
control (AA8) and XRCC4-deﬁcient (XR1) cells were analysed by
immunoblotting. (C) MRC5BIVA cells were transiently transfected
with N-terminal FLAG-tagged XLF (F-XLF) or empty vector
(F) and 500mg of WCE from both conditions were incubated with
a-FLAG antibodies. The immunoprecipitates were analysed with
a-DNA ligase IV antibodies after washing with buﬀer containing
0.12, 0.5 or 1M NaCl. The blots were also analysed with a-FLAG
antibodies to check for the presence of FLAG-tagged XLF (bottom
panel). The interaction between XLF and LX is disrupted at 1M
NaCl. (D) HIS–LigIV, MYC–XRCC4 and FLAG–XLF were expressed
individually in an in vitro transcription and translation (TNT) system in
the presence of S
35methionine, mixed and immunoprecipitated using
a-MYC antibodies. Immunoprecipitates were washed in 0.12 or 1M
NaCl. The samples washed with 1M NaCl have distorted (wider
lanes). No FLAG–XLF was detected from immunoprecipitates
washed at 1M NaCl.
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cipitated using a-MYC antibodies under both salt condi-
tions. XLF also co-immunoprecipitated with XRCC4 in
the absence of DNA ligase IV, consistent with previous
ﬁndings that the interaction is via XRCC4 (15).
These ﬁndings show that despite their predicted struc-
tural similarity, XLF cannot substitute for XRCC4 in
stabilizing DNA ligase IV and that the LX complex repre-
sents a functional heterodimer with XLF representing a
weaker binding partner.
2BNcells show a3-foldslower rate ofDSB rejoining
Despite the diﬀerent impacts of XLF and LX on ligation,
with LX being essential and XLF providing a modest
stimulation, patients with mutations in XLF and DNA
ligase IV have overlapping clinical features. To examine
loss of XLF function on ds ligation in vivo, we monitored
DSB rejoining in two XLF-defective cell lines (2BN and
F07/402) by enumerating the rate of loss of g-H2AX foci
following exposure to 3Gy IR in G0/G1 phase primary
cells (36). We included two LIG4 cell lines for comparison
(Figure 4A). Since DNA ligase IV is essential, all LIG4
cell lines harbour hypomorphic mutations. 180BR is
derived from a patient with mild clinical features (no
overt immunodeﬁciency), whilst 495GOS, was derived
from a LIG4 syndrome patient with more severe clinical
features of similar severity to those displayed by the 2BN
patient. The second XLF defective patient, F07/402, was
similar in severity displaying SCID, microcephaly and
developmental delay. Both XLF-deﬁcient cell lines
showed slow but residual DSB rejoining similar to that
observed in the LIG4 cell lines. In contrast, a DNA
ligase IV null mouse embryo ﬁbroblast (MEF) displayed
almost no detectable DSB rejoining when held in G0
phase up to 72h post irradiation (Figure 4B). Similar
results were obtained with the Chinese Hamster Ovary
(CHO) cell line, XR-1, which is defective in XRCC4
(Supplementary Figure S3).
The interpretation of these ﬁndings requires an evalua-
tion of the impact of the mutational changes. F07/402
harbours a homozygous R57X (C169T) mutation, which
is predicted to result in a severely truncated protein. Even
a point mutational change at R57, which was observed in
another XLF patient and was modelled onto the XLF
structure, was predicted to be highly destabilizing (7,18).
Thus, it is highly likely that this cell line will not retain
residual XLF function. We were unable to examine XLF
expression in these poorly growing cells. 2BN cells har-
bour a homozygous 11insT mutation and have no detect-
able residual XLF protein (Figure 3B). Even if there was a
low level of read through of the termination codon at
position 139, the majority of the cDNA would be out of
frame and likely non-functional. However, the use of
Figure 4. 2BN cells show reduced DSB rejoining. (A) Human primary ﬁbroblasts from control (1BR3), XLF-deﬁcient (2BN and F07/402) and LIG4
syndrome patients (180BR and 495GOS) were irradiated (3Gy) and the rate of loss of g-H2AX foci enumerated using a-g-H2AX antibody. Results
are the mean and SD of at least three experiments. The rate of DSB repair in 2BN and F07/402 cells is similar to that of LIG4 syndrome cell lines.
(B) The rate of DSB repair was also analysed in MEFs defective in DNA ligase IV (LigIV
 / p53
 / ) as in (A). Compared with control, the
LigIV
 / p53
 /  show no detectable rejoining up to 72h post irradiation (3Gy). (C) C-HA-XLF
WT (XLF), C-HA-XLF
11insT (11insT) and empty
vector (HA) were transfected into MRC5BIVA cells. XLF was immunoprecipitated from 500mg WCE using a-HA antibodies. WCE (50mg) and
a-HA immunoprecipitates (HA-IP) were analysed with a-HA or a-XLF antibodies. No smaller products were detectable in cells transfected with
either XLF or 11insT-XLF. (D) Downregulation of XLF reduced the rate of DSB repair in control but not 2BN (XLF-deﬁcient) cells. 1BRhT
(control) and 2BNhT (XLF-deﬁcient) were untreated or treated with siXLF and the rate of loss of g-H2AX foci enumerated after irradiation (3Gy).
The results represent the mean and SD of three experiments. Cells treated with scrambled siRNA gave identical results to untreated cells.
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C-terminal fragment could potentially lead to residual
activity. Using polyclonal antibodies raised to bacterially
expressed full-length human XLF protein (a-XLF), we
failed to detect expression of any fragments in 2BN cell
extracts of the anticipated size (data not shown). To exam-
ine further whether a downstream initiation codon
might be utilized, we transfected wild type or mutant
C-terminal HA-tagged XLF cDNA (C-HA-XLF
WT or
C-HA-XLF
11insT) into MRC5BIVA cells and examined
protein expression using a-XLF and a-HA antibodies
from cell extracts or following immunoprecipitation
using a-HA antibodies. Transfection with C-HA-XLF
WT
cDNA resulted in expression of XLF detectable using
a-XLF and a-HA antibodies, either with or without
a-HA immunoprecipitation. No residual XLF protein or
any smaller fragments were detectable following transfec-
tion with C-HA-XLF
11insT cDNA (Figure 4C). Indeed, the
only bands present were those observed using an empty
vector expressing HA alone. We conclude that there is
unlikely to be residual expression of C-terminal XLF frag-
ments in 2BN cells.
To gain further evidence that 2BN cells might lack resi-
dual XLF function, we carried out XLF siRNA using
1BRhT cells and observed impaired DSB rejoining
albeit less marked than that observed in 2BNhT cells
(Figure 4D). Notably, the DSB rejoining in 2BNhT cells
subjected to XLF siRNA was unchanged. Together, these
ﬁndings provide strong evidence that 2BN cells are unli-
kely to retain signiﬁcant residual XLF expression and
hence function. Since their rate of DSB rejoining is
reduced only 3-fold compared to control cells, this
strongly suggests that XLF facilitates but is not essential
for NHEJ.
2BN cells aresimilarly impaired in rejoining DSBs
induced by Etoposideand Neocarzinostatin
To examine whether XLF might be required for the repair
of a speciﬁc class of DNA ends, we examined the rate of
DSB repair in 2BN following exposure to two additional
DNA damaging agents that induce diﬀerent types of
DSBs. Neocarzinostatin produces a relatively homoge-
nous type of DSB possessing 30 phosphoglycolate and 50
phosphate termini, which lack the complexity of radiation
induced DSBs. Etoposide, an inhibitor of topoisomerase
II, also induces a homogenous class of DSB bound by an
inactive topoisomerase II molecule. The rate of DSB
repair was reduced to a similar magnitude in 2BN cells
compared to that observed in LigIV syndrome cell lines
suggesting impaired rejoining of multiple classes of DSBs
(Figure 5A and B).
DISCUSSION
XLF, a recently identiﬁed component of the NHEJ
machinery, is structurally related to XRCC4 (18,19) and
can promote the ligation step of NHEJ. Two impacts for
XLF on ligation have been described; ﬁrst, the stimulation
of ligation has been suggested to occur via an end-bridging
mechanism (22,33) and second, XLF has been reported to
promote the ligation of mismatched and noncohesive
DNA ends (26).
We examined the impact of XLF on LX activities. XLF
stimulated LX adenylation activity following de-adenyla-
tion by PPi treatment, and also promoted its re-adenyla-
tion following ligation, a rate limiting reaction. As a
consequence of this recharging, we observed a stimulation
of LX-mediated ds ligation under physiological concentra-
tions of ATP. This stimulation did not occur in the pre-
sence of an ATP analogue that cannot be hydrolysed to
AMP and PPi. Taken together, our ﬁndings show that
XLF enhances a range of LX activities in the presence
or absence of DNA. A fundamental impact on LX activ-
ities is consistent with structural studies and demonstrates
an eﬀect that does not depend solely on enhanced end-
bridging (18,19).
XRCC4 has also been shown to stimulate adenylation
in the absence of DNA (37). We have not been able to
express suﬃcient levels of DNA ligase IV alone to examine
whether XLF stimulates DNA ligase IV in the absence of
XRCC4. However, since our experiments are conducted
with LX complexes, the impact of XLF must be additive
to any impact of XRCC4.
XRCC4 and DNA ligase IV form a stable complex
(35,38). Moreover, DNA ligase IV is poorly expressed
in vivo and in vitro in the absence of XRCC4 and, although
less dramatic, XRCC4 expression is reduced in vivo in the
absence of DNA ligase IV (Figure 3B) (34,38). In contrast,
2BN cells, despite having no detectable XLF protein or
residual function, have normal levels of XRCC4 and
Figure 5. 2BN cells show reduce DSB rejoining after Neocarzinostatin and Etoposide. (A) Control (1BR3hT), XLF-deﬁcient (2BNhT) and LIG4
syndrome (180BRhT and GOShT) cells were analysed for g-H2AX foci loss following exposure to 50ng/ml of Neocarzinostatin (NCS). (B) 1BR3hT,
2BNhT and 180BRhT cells were analysed for g-H2AX foci loss after exposure to 20mM of Etoposide.
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of DNA ligase IV. The interaction of XLF with LX is
severely reduced even at moderate ionic strength
( 0.3M NaCl) and, although we were able to co-express
XLF, XRCC4 and DNA ligase IV in insect cells, we failed
to purify an intact complex with XLF separating from the
LX complex even following a mild puriﬁcation procedure.
Collectively, our ﬁndings demonstrate that the XLF–
XRCC4–DNA ligase IV relationship is not an equal part-
nership with XLF being less tightly bound to the strongly
associated XRCC4–DNA LigIV heterodimer. Moreover,
XLF cannot fulﬁl an important function of XRCC4,
namely the stabilization and solubilization of DNA
ligase IV. These ﬁndings are consistent with the recently
described structural studies on XLF, which have revealed
a structure that overlaps with, but is distinct, to XRCC4
(18,19). Our ﬁndings are also consistent with a study
showing that XLF does not impact on LX association
or recruitment to DSBs (16).
The clinical features of LIG4 syndrome and XLF-
deﬁcient patients are overlapping, which is, perhaps, sur-
prising given that XLF stimulates but is non-essential for
LX activity. We compared two XLF-deﬁcient cell lines,
F07/402 and 2BN, with two LIG4-deﬁcient lines. Since
LIG4 is essential, all LIG4 cell lines harbour hypomorphic
mutations with residual protein being detectable, and resi-
dual activity, where analysed in detail, ranging from 1%
to 10% of control activity (28,39). 180BR cells were
derived from a mild LIG4 patient who did not display
overt immunodeﬁciency but showed an over-response to
radiotherapy. The cells harbour a homozygous point
mutational change (R287H) that reduces LIG4 ds ligation
activity (9). 495GOS cells were derived from a more clini-
cally severe patient who required bone marrow transplan-
tation at an early age but expressed detectable residual
DNA ligase IV protein. The two XLF patients also had
severe immunodeﬁciency that necessitated bone marrow
transplantation (6) (unpublished clinical investigations).
2BN cells retain little, if any, residual function since (i)
the mutation causes a highly truncated protein with no
evidence of re-initiation, (ii) there is no detectable residual
protein and (iii) there is no added impact of XLF siRNA
on DSB repair. Whilst LigIV and XRCC4 null cell lines
show a near lack of DSB rejoining in G0 phase, the LIG4
and XLF patient cell lines show markedly impaired but
residual DSB rejoining. The residual DSB rejoining in
LIG4 syndrome cell lines demonstrates the substantial
residual DSB rejoining conferred by the hypomorphic
mutations. Interestingly, the 180BR cell line, derived
from the clinically mild patient, displays a slightly milder
DSB repair defect in the gH2AX assay compared to the
more clinically severe 495GOS patient (Figure 4A). The
DSB repair defects in both XLF cell lines lie between
the two LIG4 syndrome cell lines. Thus, despite the diﬀer-
ential impacts of XLF and DNA ligase IV on ligation
activity in vitro, the patient cell lines display overlapping
DSB repair deﬁciencies, providing an explanation for their
overlapping clinical features. Although it is diﬃcult to
entirely rule out the impact of low residual XLF activity,
these cellular studies, taken together with our biochemical
analysis, strongly suggest that, unlike DNA ligase IV and
XRCC4, which are essential for NHEJ, XLF is facilitating
but non-essential and enhances DSB rejoining around
3-fold in vivo. Recently, Li et al. 2008 (40) described an
XLF-deﬁcient mouse deleted for exons 4/5. Although it is
unclear if this represents a null phenotype, the mouse was
viable unlike XRCC4 and DNA ligase IV null mice. Since
the essential role of XRCC4 and DNA ligase IV appears
to represent NHEJ, this ﬁnding is consistent with our
notion that XLF has a non-essential role in NHEJ com-
pared to XRCC4 and DNA ligase IV. Interestingly, XLF
appears to be dispensable for lymphoid development in
mice suggesting that in lymphoid cells, at least, it is not
an essential NHEJ component.
On the basis of our ﬁndings, we propose a working
model whereby LX can be recharged in situ following
ligation to promote ds ligation by a single DNA ligase
IV molecule. The reduced rate of DSB rejoining in the
absence of XLF could reﬂect its occurrence by two inde-
pendent ligation events. The stoichiometry of NHEJ
rejoining proteins is currently unknown. It is likely that
a Ku heterodimer binds to a DSB end and recruits one
DNA–PKcs subunit per end. However, whether one or
two ligase complexes are recruited to carry out the two
ligation reactions is currently unclear. The recent struc-
tural studies show that the interaction between XRCC4
and XLF occurs through their head domains, but the
exact stoichiometry of the complex has not been deﬁned
(18,19). Li et al. suggested that the most consistent stoi-
chiometry was a 2:2:1 XRCC4–XLF–ligase IV complex
but the number of these complexes at a DSB is not
clear. Our model would predict a complex which would
only contain a single molecule of ligase IV.
XLF has also been shown to promote rejoining of mis-
matched and non-cohesive ends in vitro (26). Our ﬁndings
are not incompatible with these results, since the ability to
recharge LX could enhance end processing linked to liga-
tion. It is important to note, however, that our ligation
uses compatible DNA ends. Furthermore, we did not
observe any evidence from our in vivo analysis for a diﬀer-
ential impact of XLF-mediated rejoining of readily ligata-
ble ends generated by Etoposide compared to ends
generated by Neocarzinostatin, which are relatively homo-
geneous and thus should all require or be independent of
XLF, nor those generated by radiation, which cover a
range of complexities. It is also noteworthy that XLF is
required for the rejoining of the signal ends generated
during V(D)J recombination in vivo, which arise as blunt
ds ends (6,7). Our ﬁndings are consistent with the ability
of XLF to enhance, but not be essential for, all DSB
rejoining in vivo. It is interesting to note also that,
Nej1p, the yeast homologue of XLF, appears to be
dispensable for NHEJ at low levels of DSBs, which
would be consistent with a non-essential role in promoting
re-adenylation (41).
In conclusion, we provide the ﬁrst demonstration that
XLF stimulates LX adenylation activity, and that this can
promote ds ligation in the presence of ATP by recharging
LX following ligation. We examine two XLF-deﬁcient
cell lines, which have little, if any, residual XLF function
and show that they have approximately 3-fold slower
DSB rejoining activity in vivo. We suggest that XLF is
490 Nucleic Acids Research, 2009, Vol. 37, No. 2non-essential for NHEJ but facilitates DSB rejoining by
enhancing LX adenylation and hence ligation. We suggest
a model whereby XLF enhances ds ligation by recharging
LX to promote ds ligation by a single DNA ligase IV
molecule.
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